Comparative study of Cefpodoxime

and to study the market potential for

’s product portfolio.
 Position
Ranbaxy & Daiichi
Sankyo combined
Merger rank top 20 global
June 2008, with pharmaceutical
Daiichi Sankyo companies.
In public
Incorporated in
1961 and went No. 1 Indian Pharma
public in 1973 Company
Started by Ranbir Global consolidated
Singh and Gurbax sales –US $ 1519 Mn
Singh 1937 (2009)
International 77%
Domestic 23%
 Rantidine Valacyclovir

Diclofenac Simvastatin

Ofloxacin Co-amoxyclav

Imipenem Ciprofloxacin

Ceftriaxone Amoxycillin

Cefpodoxime Isotretinoin

Atorvastatin Ketorolac

Cephalexin Loratadine
Ginseng
 (Cefpodoxime proxetil) is an orally
administered, extended spectrum, semi-
syntheticantibiotic of the cephalosporin class.
 Microbiology:
Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-
negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase
enzymes. As a result, many organisms resistant to penicillins and
cephalosporins, due to their production of beta-lactamase, may be susceptible
to cefpodoxime.

 FOR PRODUCT PORTFOLIO

◦ CEPODEM-XP (Cefpodoxime + Clavulanic Acid)
◦ CEROXIM (Cefuroxime)
◦ CEROXIM-XP (Cefuroxime + Clavulanic Acid)
◦ RACIPER (Esomeprazole)
◦ RICONIA (Multivitamin)
◦ ALTRAFLAM (Aceclofenac)
◦ SYNASMA (Doxofylline)
◦ & GEMBAX (Gemifloxacin)
1 To know the market share of the
Ranbaxy’s Products in Ranbaxy
(Pharma) Section.

2 To know about the current products that

are giving a tough competition to
Ranbaxy.

3 To know about the new competitors that

have entered into the market and are
trying to capture some of it’s share.
Type of Research: Exploratory research
Sample unit: Retailer
Sample extent: South Delhi
Sampling technique: Convenient sampling
Sample size: 100 Retailers
Data collection methods:
Primary methods: (a)Face to face interactions (b) Questionnaire
Secondary methods: Company manuals ,Journals ,Magazines & Internet
Analysis technique
Microsoft Excel has been used for the statistical analysis.
Limitations:
Sometime respondents refuse to cooperate and it may possible that they
give biased and dishonest answers.
SALE OF CEPODEM STRIP/WEEK
 Ranbaxy Product sales/week
90

80

70

60

50

40

30

20

10

0
CEPODEM CEPODEM-XP CEROXIM CEROXIM-XP RACIPER RICONIA ALTRAFLAM-P SYNASMA GEMBAX

OVERALL AIIMS MALVIYA NAGAR CHITTARANJAN PARK

JANGPURA---BHOGAL NEW FRIENDS COLONY JAMIA NAGAR(OKHLA) OKHLA (FORTIS HOSPITAL)
Frequent Doctors Visit.

Availability of products

More profit and replacement

schemes to the chemists

Advertisement in medical journals.

Cost factor